MAOB and Parkinson disease: The present Parkinson Disease Medication (PD MED) study was a large pragmatic real-life randomized clinical trial addressing 2 questions about people with PD who experience motor complications: (1) with respect to quality of life and cost-effectiveness, is a DRI, either an MAO-B or COMT inhibitor, or a dopamine agonist more effective as adjuvant treatment for patients receiving levodopa therapy?